Otsuka Reports Phase 3b SIMTRIYO Data in ADHD and Anxiety
PRINCETON, N.J. and TOKYO, Japan — September 18, 2026 Otsuka Pharmaceutical presented new Phase 3b results for SIMTRIYO® (centanafadine)...
neuroscience
Advertisement
Alkermes Reports Positive Phase 1b ADHD Data for ALKS 7290
DUBLIN — September 21, 2026 Alkermes announced positive topline results from a Phase 1b proof-of-concept study of ALKS 7290,...
Johnson & Johnson Reports Positive CAPLYTA Phase 3 Mania Data
Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...
AbbVie Reports New Real-World VRAYLAR Data in Depression
North Chicago, Illinois, September 18, 2026 AbbVie has announced new real-world data for VRAYLAR® (cariprazine) presented at Psych Congress...
ReEmerge Raises $37M to Advance Brain Injury Technology
Boston, Massachusetts, U.S., September 15, 2026 ReEmerge, Inc. has emerged from stealth with an oversubscribed $37 million Series A...
Advertisements
QurCan Therapeutics and Lilly Advance Nucleic Acid Therapies
Cambridge, Massachusetts, September 15, 2026 QurCan Therapeutics has entered into a strategic research and collaboration agreement with Eli Lilly...
Lundbeck Completes Enrollment in Phase III Dravet Trial
Copenhagen, Denmark, September 15, 2026 H. Lundbeck A/S has announced that the last patient has been randomized in DEEp...
Johnson & Johnson Highlights New Neuropsychiatry Data
Titusville, New Jersey, U.S., September 8, 2026 Johnson & Johnson is set to present new clinical and real-world evidence...
Lundbeck Advances Bexicaserin Research in Rare Epilepsy
Valby, Denmark, September 3, 2026 H. Lundbeck A/S will present new mechanistic and clinical research on bexicaserin (LP352) at...
Newron Completes Screening for Phase 3 Evenamide TRS Study
MILAN, Italy and MORRISTOWN, N.J., September 2, 2026 Newron Pharmaceuticals S.p.A. announced completion of screening for enrollment in its...
Advertisement
